BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Orion Genomics Announces The Discovery And Validation Of Novel Breast Cancer Biomarkers


12/19/2006 10:18:17 AM

ST. LOUIS, Dec. 19 /PRNewswire/ -- Orion Genomics announced today that the company has identified and validated a suite of novel breast cancer biomarkers, the most promising of which will be incorporated into the company's diagnostic assays for the early detection of breast cancer and the detection of breast cancer recurrence. Using proprietary genome-wide microarray technology, the company was able to quickly identify a suite of novel biomarkers in a panel consisting of normal and cancerous breast tissues. In a second independent biomarker validation panel of more than 200 normal and cancerous breast tissues, over 50 biomarkers demonstrated significant diagnostic potential, the most promising of which presented 90 percent sensitivity and 96 percent specificity. The results of Orion's genome-wide, DNA methylation profiling were presented at the 29th Annual San Antonio Breast Cancer Symposium on December 14, 2006 in San Antonio, Texas.

"Utilizing MethylScope(R), our genome-wide DNA methylation profiling technology, we were able to quickly identify a suite of promising breast cancer biomarkers that show significantly high sensitivity and specificity and represent the most comprehensive and clinically accurate breast cancer epigenetic biomarkers discovered to date," said Jorge A. Leon, Ph.D., Orion's acting Chief Scientific Officer. "We are now validating our most promising biomarkers in blood serum from cancer-free and breast cancer patients."

According to the American Cancer Society, an estimated 211,000 new cases of invasive breast cancer are expected in the U.S. in 2006 alone, where approximately 40,000 patients are expected to die of their disease. Early detection and treatment when the tumor is still small remains a key factor in survival; however, early stage breast cancer typically produces no noticeable symptoms, making early detection through conventional methods challenging.

"Identifying cancer earlier in the disease progression timeline will significantly improve treatment outcomes and patient survival, especially in breast cancer," said Nathan Lakey, Chief Executive Officer and president of Orion Genomics. "Our identification and validation of sensitive and specific biomarkers for the detection of breast cancer will form the foundation of our breast cancer diagnostic assays. These assays will provide a diagnostic screening test, from blood or other easily collected samples, of a large population for the early or recurrent signs of breast cancer."

About Orion Genomics

Orion Genomics, the Second Code biotechnology company, develops molecular diagnostic products to detect cancer at its earliest stages and to aid in appropriate therapy selection. Orion's most advanced diagnostic program is in breast cancer, where the company is developing a highly sensitive and selective early screening test, followed by additional epigenetic screening assays in lung, ovarian and colon cancers. Orion Genomics is located in the Center for Emerging Technologies in St. Louis. For more information, visit http://www.oriongenomics.com.

Orion Genomics

CONTACT: Amy Blackley, Ph.D., of Porter Novelli Life Sciences,+1-619-849-6008, ablackley@pnlifesciences.com, for Orion Genomics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES